Global Cancer Biopharmaceuticals Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 311183
  • calendar_today Published On: Jun, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Cancer Biopharmaceuticals market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Cancer Biopharmaceuticals market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Liquid Cancers accounting for % of the Cancer Biopharmaceuticals global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Biologics segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Cancer Biopharmaceuticals include Sanofi, Johnson & Johnson, Pfizer, Novartis, and Merck, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Cancer Biopharmaceuticals market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Biologics

Biosimilars

Market segment by Application, can be divided into

Liquid Cancers

Solid Cancers

Market segment by players, this report covers

Sanofi

Johnson & Johnson

Pfizer

Novartis

Merck

GlaxoSmithKline

Eli Lilly

Agios Pharmaceuticals

Bristol-Myers Squibb

AstraZeneca

Mylan

LEO Pharma

Boehringer Ingelheim

Alexion Pharmaceuticals

Elusys Therapeutics

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Cancer Biopharmaceuticals product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Cancer Biopharmaceuticals, with revenue, gross margin and global market share of Cancer Biopharmaceuticals from 2019 to 2022.

Chapter 3, the Cancer Biopharmaceuticals competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Cancer Biopharmaceuticals market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Cancer Biopharmaceuticals research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Cancer Biopharmaceuticals

1.2 Classification of Cancer Biopharmaceuticals by Type

1.2.1 Overview: Global Cancer Biopharmaceuticals Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Cancer Biopharmaceuticals Revenue Market Share by Type in 2021

1.2.3 Biologics

1.2.4 Biosimilars

1.3 Global Cancer Biopharmaceuticals Market by Application

1.3.1 Overview: Global Cancer Biopharmaceuticals Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Liquid Cancers

1.3.3 Solid Cancers

1.4 Global Cancer Biopharmaceuticals Market Size & Forecast

1.5 Global Cancer Biopharmaceuticals Market Size and Forecast by Region

1.5.1 Global Cancer Biopharmaceuticals Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Cancer Biopharmaceuticals Market Size by Region, (2017-2022)

1.5.3 North America Cancer Biopharmaceuticals Market Size and Prospect (2017-2028)

1.5.4 Europe Cancer Biopharmaceuticals Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Cancer Biopharmaceuticals Market Size and Prospect (2017-2028)

1.5.6 South America Cancer Biopharmaceuticals Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Cancer Biopharmaceuticals Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Cancer Biopharmaceuticals Market Drivers

1.6.2 Cancer Biopharmaceuticals Market Restraints

1.6.3 Cancer Biopharmaceuticals Trends Analysis

2 Company Profiles

2.1 Sanofi

2.1.1 Sanofi Details

2.1.2 Sanofi Major Business

2.1.3 Sanofi Cancer Biopharmaceuticals Product and Solutions

2.1.4 Sanofi Cancer Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Sanofi Recent Developments and Future Plans

2.2 Johnson & Johnson

2.2.1 Johnson & Johnson Details

2.2.2 Johnson & Johnson Major Business

2.2.3 Johnson & Johnson Cancer Biopharmaceuticals Product and Solutions

2.2.4 Johnson & Johnson Cancer Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Johnson & Johnson Recent Developments and Future Plans

2.3 Pfizer

2.3.1 Pfizer Details

2.3.2 Pfizer Major Business

2.3.3 Pfizer Cancer Biopharmaceuticals Product and Solutions

2.3.4 Pfizer Cancer Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Pfizer Recent Developments and Future Plans

2.4 Novartis

2.4.1 Novartis Details

2.4.2 Novartis Major Business

2.4.3 Novartis Cancer Biopharmaceuticals Product and Solutions

2.4.4 Novartis Cancer Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Novartis Recent Developments and Future Plans

2.5 Merck

2.5.1 Merck Details

2.5.2 Merck Major Business

2.5.3 Merck Cancer Biopharmaceuticals Product and Solutions

2.5.4 Merck Cancer Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Merck Recent Developments and Future Plans

2.6 GlaxoSmithKline

2.6.1 GlaxoSmithKline Details

2.6.2 GlaxoSmithKline Major Business

2.6.3 GlaxoSmithKline Cancer Biopharmaceuticals Product and Solutions

2.6.4 GlaxoSmithKline Cancer Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 GlaxoSmithKline Recent Developments and Future Plans

2.7 Eli Lilly

2.7.1 Eli Lilly Details

2.7.2 Eli Lilly Major Business

2.7.3 Eli Lilly Cancer Biopharmaceuticals Product and Solutions

2.7.4 Eli Lilly Cancer Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Eli Lilly Recent Developments and Future Plans

2.8 Agios Pharmaceuticals

2.8.1 Agios Pharmaceuticals Details

2.8.2 Agios Pharmaceuticals Major Business

2.8.3 Agios Pharmaceuticals Cancer Biopharmaceuticals Product and Solutions

2.8.4 Agios Pharmaceuticals Cancer Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Agios Pharmaceuticals Recent Developments and Future Plans

2.9 Bristol-Myers Squibb

2.9.1 Bristol-Myers Squibb Details

2.9.2 Bristol-Myers Squibb Major Business

2.9.3 Bristol-Myers Squibb Cancer Biopharmaceuticals Product and Solutions

2.9.4 Bristol-Myers Squibb Cancer Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Bristol-Myers Squibb Recent Developments and Future Plans

2.10 AstraZeneca

2.10.1 AstraZeneca Details

2.10.2 AstraZeneca Major Business

2.10.3 AstraZeneca Cancer Biopharmaceuticals Product and Solutions

2.10.4 AstraZeneca Cancer Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 AstraZeneca Recent Developments and Future Plans

2.11 Mylan

2.11.1 Mylan Details

2.11.2 Mylan Major Business

2.11.3 Mylan Cancer Biopharmaceuticals Product and Solutions

2.11.4 Mylan Cancer Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Mylan Recent Developments and Future Plans

2.12 LEO Pharma

2.12.1 LEO Pharma Details

2.12.2 LEO Pharma Major Business

2.12.3 LEO Pharma Cancer Biopharmaceuticals Product and Solutions

2.12.4 LEO Pharma Cancer Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 LEO Pharma Recent Developments and Future Plans

2.13 Boehringer Ingelheim

2.13.1 Boehringer Ingelheim Details

2.13.2 Boehringer Ingelheim Major Business

2.13.3 Boehringer Ingelheim Cancer Biopharmaceuticals Product and Solutions

2.13.4 Boehringer Ingelheim Cancer Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Boehringer Ingelheim Recent Developments and Future Plans

2.14 Alexion Pharmaceuticals

2.14.1 Alexion Pharmaceuticals Details

2.14.2 Alexion Pharmaceuticals Major Business

2.14.3 Alexion Pharmaceuticals Cancer Biopharmaceuticals Product and Solutions

2.14.4 Alexion Pharmaceuticals Cancer Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 Alexion Pharmaceuticals Recent Developments and Future Plans

2.15 Elusys Therapeutics

2.15.1 Elusys Therapeutics Details

2.15.2 Elusys Therapeutics Major Business

2.15.3 Elusys Therapeutics Cancer Biopharmaceuticals Product and Solutions

2.15.4 Elusys Therapeutics Cancer Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.15.5 Elusys Therapeutics Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Cancer Biopharmaceuticals Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Cancer Biopharmaceuticals Players Market Share in 2021

3.2.2 Top 10 Cancer Biopharmaceuticals Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Cancer Biopharmaceuticals Players Head Office, Products and Services Provided

3.4 Cancer Biopharmaceuticals Mergers & Acquisitions

3.5 Cancer Biopharmaceuticals New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Cancer Biopharmaceuticals Revenue and Market Share by Type (2017-2022)

4.2 Global Cancer Biopharmaceuticals Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Cancer Biopharmaceuticals Revenue Market Share by Application (2017-2022)

5.2 Global Cancer Biopharmaceuticals Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Cancer Biopharmaceuticals Revenue by Type (2017-2028)

6.2 North America Cancer Biopharmaceuticals Revenue by Application (2017-2028)

6.3 North America Cancer Biopharmaceuticals Market Size by Country

6.3.1 North America Cancer Biopharmaceuticals Revenue by Country (2017-2028)

6.3.2 United States Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

6.3.3 Canada Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

6.3.4 Mexico Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Cancer Biopharmaceuticals Revenue by Type (2017-2028)

7.2 Europe Cancer Biopharmaceuticals Revenue by Application (2017-2028)

7.3 Europe Cancer Biopharmaceuticals Market Size by Country

7.3.1 Europe Cancer Biopharmaceuticals Revenue by Country (2017-2028)

7.3.2 Germany Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

7.3.3 France Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

7.3.5 Russia Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

7.3.6 Italy Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Cancer Biopharmaceuticals Revenue by Type (2017-2028)

8.2 Asia-Pacific Cancer Biopharmaceuticals Revenue by Application (2017-2028)

8.3 Asia-Pacific Cancer Biopharmaceuticals Market Size by Region

8.3.1 Asia-Pacific Cancer Biopharmaceuticals Revenue by Region (2017-2028)

8.3.2 China Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

8.3.3 Japan Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

8.3.4 South Korea Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

8.3.5 India Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

8.3.7 Australia Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Cancer Biopharmaceuticals Revenue by Type (2017-2028)

9.2 South America Cancer Biopharmaceuticals Revenue by Application (2017-2028)

9.3 South America Cancer Biopharmaceuticals Market Size by Country

9.3.1 South America Cancer Biopharmaceuticals Revenue by Country (2017-2028)

9.3.2 Brazil Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

9.3.3 Argentina Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Cancer Biopharmaceuticals Revenue by Type (2017-2028)

10.2 Middle East & Africa Cancer Biopharmaceuticals Revenue by Application (2017-2028)

10.3 Middle East & Africa Cancer Biopharmaceuticals Market Size by Country

10.3.1 Middle East & Africa Cancer Biopharmaceuticals Revenue by Country (2017-2028)

10.3.2 Turkey Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

10.3.4 UAE Cancer Biopharmaceuticals Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Cancer Biopharmaceuticals Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Cancer Biopharmaceuticals Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Cancer Biopharmaceuticals Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Cancer Biopharmaceuticals Revenue (USD Million) by Region (2017-2022)

Table 5. Global Cancer Biopharmaceuticals Revenue Market Share by Region (2023-2028)

Table 6. Sanofi Corporate Information, Head Office, and Major Competitors

Table 7. Sanofi Major Business

Table 8. Sanofi Cancer Biopharmaceuticals Product and Solutions

Table 9. Sanofi Cancer Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Johnson & Johnson Corporate Information, Head Office, and Major Competitors

Table 11. Johnson & Johnson Major Business

Table 12. Johnson & Johnson Cancer Biopharmaceuticals Product and Solutions

Table 13. Johnson & Johnson Cancer Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Pfizer Corporate Information, Head Office, and Major Competitors

Table 15. Pfizer Major Business

Table 16. Pfizer Cancer Biopharmaceuticals Product and Solutions

Table 17. Pfizer Cancer Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Novartis Corporate Information, Head Office, and Major Competitors

Table 19. Novartis Major Business

Table 20. Novartis Cancer Biopharmaceuticals Product and Solutions

Table 21. Novartis Cancer Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Merck Corporate Information, Head Office, and Major Competitors

Table 23. Merck Major Business

Table 24. Merck Cancer Biopharmaceuticals Product and Solutions

Table 25. Merck Cancer Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors

Table 27. GlaxoSmithKline Major Business

Table 28. GlaxoSmithKline Cancer Biopharmaceuticals Product and Solutions

Table 29. GlaxoSmithKline Cancer Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Eli Lilly Corporate Information, Head Office, and Major Competitors

Table 31. Eli Lilly Major Business

Table 32. Eli Lilly Cancer Biopharmaceuticals Product and Solutions

Table 33. Eli Lilly Cancer Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Agios Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 35. Agios Pharmaceuticals Major Business

Table 36. Agios Pharmaceuticals Cancer Biopharmaceuticals Product and Solutions

Table 37. Agios Pharmaceuticals Cancer Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors

Table 39. Bristol-Myers Squibb Major Business

Table 40. Bristol-Myers Squibb Cancer Biopharmaceuticals Product and Solutions

Table 41. Bristol-Myers Squibb Cancer Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. AstraZeneca Corporate Information, Head Office, and Major Competitors

Table 43. AstraZeneca Major Business

Table 44. AstraZeneca Cancer Biopharmaceuticals Product and Solutions

Table 45. AstraZeneca Cancer Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Mylan Corporate Information, Head Office, and Major Competitors

Table 47. Mylan Major Business

Table 48. Mylan Cancer Biopharmaceuticals Product and Solutions

Table 49. Mylan Cancer Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. LEO Pharma Corporate Information, Head Office, and Major Competitors

Table 51. LEO Pharma Major Business

Table 52. LEO Pharma Cancer Biopharmaceuticals Product and Solutions

Table 53. LEO Pharma Cancer Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors

Table 55. Boehringer Ingelheim Major Business

Table 56. Boehringer Ingelheim Cancer Biopharmaceuticals Product and Solutions

Table 57. Boehringer Ingelheim Cancer Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Alexion Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 59. Alexion Pharmaceuticals Major Business

Table 60. Alexion Pharmaceuticals Cancer Biopharmaceuticals Product and Solutions

Table 61. Alexion Pharmaceuticals Cancer Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. Elusys Therapeutics Corporate Information, Head Office, and Major Competitors

Table 63. Elusys Therapeutics Major Business

Table 64. Elusys Therapeutics Cancer Biopharmaceuticals Product and Solutions

Table 65. Elusys Therapeutics Cancer Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 66. Global Cancer Biopharmaceuticals Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 67. Global Cancer Biopharmaceuticals Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 68. Breakdown of Cancer Biopharmaceuticals by Company Type (Tier 1, Tier 2 and Tier 3)

Table 69. Cancer Biopharmaceuticals Players Head Office, Products and Services Provided

Table 70. Cancer Biopharmaceuticals Mergers & Acquisitions in the Past Five Years

Table 71. Cancer Biopharmaceuticals New Entrants and Expansion Plans

Table 72. Global Cancer Biopharmaceuticals Revenue (USD Million) by Type (2017-2022)

Table 73. Global Cancer Biopharmaceuticals Revenue Share by Type (2017-2022)

Table 74. Global Cancer Biopharmaceuticals Revenue Forecast by Type (2023-2028)

Table 75. Global Cancer Biopharmaceuticals Revenue by Application (2017-2022)

Table 76. Global Cancer Biopharmaceuticals Revenue Forecast by Application (2023-2028)

Table 77. North America Cancer Biopharmaceuticals Revenue by Type (2017-2022) & (USD Million)

Table 78. North America Cancer Biopharmaceuticals Revenue by Type (2023-2028) & (USD Million)

Table 79. North America Cancer Biopharmaceuticals Revenue by Application (2017-2022) & (USD Million)

Table 80. North America Cancer Biopharmaceuticals Revenue by Application (2023-2028) & (USD Million)

Table 81. North America Cancer Biopharmaceuticals Revenue by Country (2017-2022) & (USD Million)

Table 82. North America Cancer Biopharmaceuticals Revenue by Country (2023-2028) & (USD Million)

Table 83. Europe Cancer Biopharmaceuticals Revenue by Type (2017-2022) & (USD Million)

Table 84. Europe Cancer Biopharmaceuticals Revenue by Type (2023-2028) & (USD Million)

Table 85. Europe Cancer Biopharmaceuticals Revenue by Application (2017-2022) & (USD Million)

Table 86. Europe Cancer Biopharmaceuticals Revenue by Application (2023-2028) & (USD Million)

Table 87. Europe Cancer Biopharmaceuticals Revenue by Country (2017-2022) & (USD Million)

Table 88. Europe Cancer Biopharmaceuticals Revenue by Country (2023-2028) & (USD Million)

Table 89. Asia-Pacific Cancer Biopharmaceuticals Revenue by Type (2017-2022) & (USD Million)

Table 90. Asia-Pacific Cancer Biopharmaceuticals Revenue by Type (2023-2028) & (USD Million)

Table 91. Asia-Pacific Cancer Biopharmaceuticals Revenue by Application (2017-2022) & (USD Million)

Table 92. Asia-Pacific Cancer Biopharmaceuticals Revenue by Application (2023-2028) & (USD Million)

Table 93. Asia-Pacific Cancer Biopharmaceuticals Revenue by Region (2017-2022) & (USD Million)

Table 94. Asia-Pacific Cancer Biopharmaceuticals Revenue by Region (2023-2028) & (USD Million)

Table 95. South America Cancer Biopharmaceuticals Revenue by Type (2017-2022) & (USD Million)

Table 96. South America Cancer Biopharmaceuticals Revenue by Type (2023-2028) & (USD Million)

Table 97. South America Cancer Biopharmaceuticals Revenue by Application (2017-2022) & (USD Million)

Table 98. South America Cancer Biopharmaceuticals Revenue by Application (2023-2028) & (USD Million)

Table 99. South America Cancer Biopharmaceuticals Revenue by Country (2017-2022) & (USD Million)

Table 100. South America Cancer Biopharmaceuticals Revenue by Country (2023-2028) & (USD Million)

Table 101. Middle East & Africa Cancer Biopharmaceuticals Revenue by Type (2017-2022) & (USD Million)

Table 102. Middle East & Africa Cancer Biopharmaceuticals Revenue by Type (2023-2028) & (USD Million)

Table 103. Middle East & Africa Cancer Biopharmaceuticals Revenue by Application (2017-2022) & (USD Million)

Table 104. Middle East & Africa Cancer Biopharmaceuticals Revenue by Application (2023-2028) & (USD Million)

Table 105. Middle East & Africa Cancer Biopharmaceuticals Revenue by Country (2017-2022) & (USD Million)

Table 106. Middle East & Africa Cancer Biopharmaceuticals Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Cancer Biopharmaceuticals Picture

Figure 2. Global Cancer Biopharmaceuticals Revenue Market Share by Type in 2021

Figure 3. Biologics

Figure 4. Biosimilars

Figure 5. Cancer Biopharmaceuticals Revenue Market Share by Application in 2021

Figure 6. Liquid Cancers Picture

Figure 7. Solid Cancers Picture

Figure 8. Global Cancer Biopharmaceuticals Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 9. Global Cancer Biopharmaceuticals Revenue and Forecast (2017-2028) & (USD Million)

Figure 10. Global Cancer Biopharmaceuticals Revenue Market Share by Region (2017-2028)

Figure 11. Global Cancer Biopharmaceuticals Revenue Market Share by Region in 2021

Figure 12. North America Cancer Biopharmaceuticals Revenue (USD Million) and Growth Rate (2017-2028)

Figure 13. Europe Cancer Biopharmaceuticals Revenue (USD Million) and Growth Rate (2017-2028)

Figure 14. Asia-Pacific Cancer Biopharmaceuticals Revenue (USD Million) and Growth Rate (2017-2028)

Figure 15. South America Cancer Biopharmaceuticals Revenue (USD Million) and Growth Rate (2017-2028)

Figure 16. Middle East and Africa Cancer Biopharmaceuticals Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. Cancer Biopharmaceuticals Market Drivers

Figure 18. Cancer Biopharmaceuticals Market Restraints

Figure 19. Cancer Biopharmaceuticals Market Trends

Figure 20. Sanofi Recent Developments and Future Plans

Figure 21. Johnson & Johnson Recent Developments and Future Plans

Figure 22. Pfizer Recent Developments and Future Plans

Figure 23. Novartis Recent Developments and Future Plans

Figure 24. Merck Recent Developments and Future Plans

Figure 25. GlaxoSmithKline Recent Developments and Future Plans

Figure 26. Eli Lilly Recent Developments and Future Plans

Figure 27. Agios Pharmaceuticals Recent Developments and Future Plans

Figure 28. Bristol-Myers Squibb Recent Developments and Future Plans

Figure 29. AstraZeneca Recent Developments and Future Plans

Figure 30. Mylan Recent Developments and Future Plans

Figure 31. LEO Pharma Recent Developments and Future Plans

Figure 32. Boehringer Ingelheim Recent Developments and Future Plans

Figure 33. Alexion Pharmaceuticals Recent Developments and Future Plans

Figure 34. Elusys Therapeutics Recent Developments and Future Plans

Figure 35. Global Cancer Biopharmaceuticals Revenue Share by Players in 2021

Figure 36. Cancer Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 37. Global Top 3 Players Cancer Biopharmaceuticals Revenue Market Share in 2021

Figure 38. Global Top 10 Players Cancer Biopharmaceuticals Revenue Market Share in 2021

Figure 39. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 40. Global Cancer Biopharmaceuticals Revenue Share by Type in 2021

Figure 41. Global Cancer Biopharmaceuticals Market Share Forecast by Type (2023-2028)

Figure 42. Global Cancer Biopharmaceuticals Revenue Share by Application in 2021

Figure 43. Global Cancer Biopharmaceuticals Market Share Forecast by Application (2023-2028)

Figure 44. North America Cancer Biopharmaceuticals Sales Market Share by Type (2017-2028)

Figure 45. North America Cancer Biopharmaceuticals Sales Market Share by Application (2017-2028)

Figure 46. North America Cancer Biopharmaceuticals Revenue Market Share by Country (2017-2028)

Figure 47. United States Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 48. Canada Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 49. Mexico Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 50. Europe Cancer Biopharmaceuticals Sales Market Share by Type (2017-2028)

Figure 51. Europe Cancer Biopharmaceuticals Sales Market Share by Application (2017-2028)

Figure 52. Europe Cancer Biopharmaceuticals Revenue Market Share by Country (2017-2028)

Figure 53. Germany Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. France Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. United Kingdom Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. Russia Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. Italy Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. Asia-Pacific Cancer Biopharmaceuticals Sales Market Share by Type (2017-2028)

Figure 59. Asia-Pacific Cancer Biopharmaceuticals Sales Market Share by Application (2017-2028)

Figure 60. Asia-Pacific Cancer Biopharmaceuticals Revenue Market Share by Region (2017-2028)

Figure 61. China Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. Japan Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. South Korea Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. India Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. Southeast Asia Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. Australia Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. South America Cancer Biopharmaceuticals Sales Market Share by Type (2017-2028)

Figure 68. South America Cancer Biopharmaceuticals Sales Market Share by Application (2017-2028)

Figure 69. South America Cancer Biopharmaceuticals Revenue Market Share by Country (2017-2028)

Figure 70. Brazil Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. Argentina Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 72. Middle East and Africa Cancer Biopharmaceuticals Sales Market Share by Type (2017-2028)

Figure 73. Middle East and Africa Cancer Biopharmaceuticals Sales Market Share by Application (2017-2028)

Figure 74. Middle East and Africa Cancer Biopharmaceuticals Revenue Market Share by Country (2017-2028)

Figure 75. Turkey Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. Saudi Arabia Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. UAE Cancer Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 78. Methodology

Figure 79. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz